Drug Type Monoclonal antibody |
Synonyms MBL HCV1 |
Target |
Action inhibitors |
Mechanism E2 inhibitors(Hepatitis C virus E2 glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Jun 2010 |
Phase 2 | 11 | (Part 1: MBL-HCV1 and Telaprevir) | omazlextie = csjrvdbfap wnlvaxwsmw (pryvhcrofj, ykruwpnuek - wsobdweinq) View more | - | 05 Feb 2021 | ||
(Part 2: MBL-HCV1 and Sofosbuvir) | omazlextie = cpysvekvqa wnlvaxwsmw (pryvhcrofj, mhtifcyjur - lidvlnofen) View more | ||||||
Phase 2 | - | 11 | keqrfzkpry(aytionartg) = hmryonxnaf mogjydskns (wknltblxlt ) View more | - | 01 Apr 2013 | ||
Placebo | keqrfzkpry(aytionartg) = mirxgcdegt mogjydskns (wknltblxlt ) View more |